Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174030 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Phase 2 study of Rosacea, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 269
- Enrollment target
- 20
- Study locations
NCT01174030: Completed Phase 2 study of Rosacea, sponsored by Galderma R&D.
NCT01174030 is a Phase 2 study of Rosacea that has completed, run by Galderma R&D. The registered enrollment target is 269 participants, above the 231-participant average among 23 other Rosacea trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01174030, a Phase 2 study of Rosacea, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 269 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this vehicle controlled study is to evaluate the efficacy and safety of CD07805/47 gel 0.5% applied topically once daily (QD) for 4 weeks, and CD07805/47 gel 0.18% applied topically once daily (QD) or twice daily (BID) for 4 weeks, in subjects with moderate to severe facial erythema associated with rosacea.
Primary Outcome
Composite success defined as 2-grade improvement on Clinician Erythema Assessment (CEA)and Patient Self Assessment-5 (PSA-5). Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.
Conditions Studied
Interventions
- DRUG Vehicle Gel
- DRUG CD07805/47 Gel
Study Locations (20)
North Carolina
- Dermatology Laser & Vein Specialists - Charlotte
- Dermatology Consulting Services - High Point
Oregon
- Oregon Dermatology & Research Center - Portland
- Oregon Medical Research - Portland
Pennsylvania
- Philadelphia Institute of Dermatology - Fort Washington
- DermDox - Hazleton
Texas
- Arlington Center for Dermatology - Arlington
- Dermatology Treatment & Research Center - Dallas
Arkansas
- Burke Pharmaceutical Research - Hot Springs
California
- University of California at San Francisco - San Francisco
Georgia
- Meda Phase, Inc - Newnan
Kentucky
- Dermatology Specialists PC - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
What the finished NCT01174030 record still lists
NCT01174030 is an interventional study that assigns participants to a tested intervention. The registered 269 participants enrollment target is mid-sized for trials with a published cap, above the 231-participant average among 23 other Rosacea trials with a reported enrollment target (16% higher).
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Vehicle Gel is the first listed.
NCT01174030 names 20 study sites across 16 states, led by North Carolina, Oregon, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01174030 about?
NCT01174030 is a clinical study titled "Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea". The purpose of this vehicle controlled study is to evaluate the efficacy and safety of CD07805/47 gel 0.5% applied topically once daily (QD) for 4 weeks, and CD07805/47 gel 0.18% applied topically once daily (QD) or twice daily (BID) for 4 weeks, in subjects with moderate to severe facial erythema a...
What is the current status of trial NCT01174030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 269 participants. The study started on 2010-08. Estimated completion is 2011-01.
What conditions does trial NCT01174030 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT01174030?
The interventions under investigation include: Vehicle Gel (DRUG), CD07805/47 Gel (DRUG).
Who is sponsoring clinical trial NCT01174030?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01174030 being conducted?
This trial has 20 study locations across Arkansas, California, Georgia, Kentucky, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01174030's enrollment target sits among peer trials
269 8th of 23 higher than 16 of 23 other Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
-
Rosacea and Ivermectin
COMPLETED · Phase 2
-
AGN-199201 for the Treatment of Erythema With Rosacea
COMPLETED · Phase 2
-
A Study of DER 45-EV Gel to Treat Rosacea
COMPLETED · Phase 2
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04802291 · 269 participants · NA
HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity
- NCT06500455 · 269 participants · Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
- NCT06630676 · 269 participants · NA
The Ability of Chronic Pain Patients to Self-diagnose Their Chief Source of Low Back Pain
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia